Capecitabine, Vorinostat, and Radiation Therapy in Treating Patients With Nonmetastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2013-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop
the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Radiation therapy uses high energy x-rays to kill tumor cells. Giving capecitabine
and vorinostat together with radiation therapy may kill more tumor cells.
PURPOSE: This phase I trial is studying the side effects and best dose of vorinostat when
given together with capecitabine and radiation therapy in treating patients with
nonmetastatic pancreatic cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Vanderbilt-Ingram Cancer Center
Collaborators:
National Cancer Institute (NCI) National Comprehensive Cancer Network